Keefe, Bruyette & Woods maintains Root at Outperform, lowers price target to $70 from $75

Keefe, Bruyette & Woods kept Root at Outperform but cut its price target to $70 from $75, a 6.7% reduction. The new target suggests 22.5% upside from the Nov 4 close of $57.15, according to the firm.

Original reporting
Published Nov 5, 2026, 6:10 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 5, 2026, 6:22 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Keefe, Bruyette & Woods maintains Root at Outperform, lowers price target to $70 from $75 — source image
Decision brief

The 30-second read

$ROOTBearishLow
01

Why it matters

The downgrade may lead to short-term selling pressure.

02

Market read

Analyst target adjustments can influence short-term price action, though the impact is modest.

03

What to watch

Potential upcoming product launches or earnings could offset the target reduction.

Relevance 4/10Novelty 4/10Timing: today

Background

KBW maintains an Outperform rating but reduces the price target, indicating a softer outlook.

Company-level read

Ticker impact

$ROOTBearishMedium confidence
Context

KBW lowered Root's price target to $70 from $75, a 6.7% decrease.

Expected impact

likely downside as investors price in the lower target

Evidence & confidence

Target cut signals weaker outlook, prompting sell pressure.

Market effects

Minor impact on the financial services sector as analysts adjust expectations.

Limited to US markets where Root trades.

Low global relevance.

Counterpoint

Some investors may view the target cut as an entry point if they believe the stock is undervalued.

Key entities

  • Keefe, Bruyette & Woods

    Equity research firm providing the rating and target.

  • Root

    Financial services firm whose stock is affected.

Related articles

$ROOTMed

Root (ROOT) Q3 2026 Earnings Call Transcript

Root (ROOT) reported Q3 2026 revenue of $381M (down from $388M YoY) and net income of $14M (vs. a $5M loss YoY). Policies in force grew 4% YoY to 484,000, while gross written premiums decreased 8%. Management highlighted pricing discipline, strategic partnerships, and geographic expansion to 38 states. They guided Q4 loss ratio to the high end of the 60-65% range due to seasonal factors.

$ROOTMed

Root Q3 Earnings Call Highlights

Root (NASDAQ:ROOT) expects policies in force at year-end to align with Q3 levels, with $5M invested in marketing and R&D. Q4 loss ratio may rise due to seasonal factors. The company repurchased $36M in shares and developed a new pricing algorithm, aiming for higher conversion rates and potential premium declines. Growth drivers for 2027 include state expansion and partnerships, though competition remains uncertain.

$ROOTMed

Root Inc (ROOT) Q3 2026 Earnings Call Highlights: Profitability Surges With $14 Million

Root Inc (ROOT) reported Q3 2026 net income of $14M, up from a $5M loss last year, with revenue at $381M. CEO Alexander Timm highlighted growth strategies, including state expansions, AI-driven pricing, and partnerships. The company aims for national reach by late 2027, with continued investment in technology and channels. ROE was 18% this quarter, 25% over the last 12 months. Policies in force rose 4% year-over-year to 484,000.

$ROOTMed

Root, Inc. (ROOT): Letter to Shareholders: Q3 2026

Root, Inc. (ROOT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Letter to Shareholders: Q3 2026 ____________________________________________________________________________________________________________ Key quarterly metrics Dear Root Shareholders In the third quarter, Root delivered another quarter of strong profitability while continuing

$ROOTMed

Root (ROOT) Q2 2026 Earnings Call Transcript

Root (ROOT) held its Q2 2026 earnings call, saying it is building an AI-driven insurance platform. Management cited 2% YoY revenue growth to $389M, gross written premium down 2% to $340M, policies in force up 6% to 484,000, and a 92.1% net combined ratio. It also reported a $200M debt facility refinance, $20M+ share repurchases, and plans to launch a new predictive pricing model later this year.

$METMed

Financial results round-up: MetLife, Prudential, Corebridge, Palomar, Heritage, TWFG, Root and more

A financial results roundup covers multiple insurers and MGAs. MetLife reported Q2 net income of $705m and adjusted EPS $2.43. Prudential posted Q2 net income of $985m and record individual life sales. Corebridge reported a $16m net loss and merger approval. Palomar, Heritage, TWFG, Root, Trupanion and Clover Health also reported Q2 figures and guidance updates.